Antiplatelet Activity of Riamilovir under Conditions of Lipopolysaccharide Intoxication

We studied the effect of antiviral agent riamilovir on ADP-induced platelet aggregation in the absence and presence of LPS. Unlike acetylsalicylic acid (reference drug), riamilovir did not exhibit antiplatelet effect in vitro. However, it markedly suppressed platelet reactivity in LPS-treated blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Spasov, A. A., Kucheryavenko, A. F., Sirotenko, V. S., Gaidukova, K. A., Uskov, G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134143/
https://www.ncbi.nlm.nih.gov/pubmed/35616790
http://dx.doi.org/10.1007/s10517-022-05489-0
Descripción
Sumario:We studied the effect of antiviral agent riamilovir on ADP-induced platelet aggregation in the absence and presence of LPS. Unlike acetylsalicylic acid (reference drug), riamilovir did not exhibit antiplatelet effect in vitro. However, it markedly suppressed platelet reactivity in LPS-treated blood samples and was 2.2-fold superior to acetylsalicylic acid in terms of IC(50) value. In in vivo experiments, riamilovir under conditions of hypercytokinemia blocked platelet aggregation in rats by 64%.

Ejemplares similares